Transthyretin amyloidosis of the heart – a diagnosis to keep in mind even in old age
Authors:
Vráblová Simona 1; Kuchynka Petr 2; Šaková Rita 1; Richter Tomáš 1; Topinková Eva 1
Authors‘ workplace:
Geriatrická klinika 1. LF UK a VFN Praha
1; II. interní klinika – klinika kardiologie a angiologie 1. LF UK a VFN Praha
2
Published in:
Geriatrie a Gerontologie 2023, 12, č. 3: 141-145
Category:
Overview
Vráblová S, Kuchynka P, Šaková R, Richter T, Topinková E. Transthyretin amyloidosis of the heart – a diagnosis to keep in mind even in old age
Transthyretin amyloidosis of the heart (ATTR) is a progressive disease caused by the deposition of insoluble transthyretin in the myocardium. Finally it can lead to heart failure. It occurs predominantly in men over the age of 70. This disease should be considered in differential diagnosis by elderly patients with heart failure, cardiac arrhythmias or conduction disorders (especially atrioventricular conduction disorders) and left ventricular wall thickening of unclear etiology. In case of suspected ATTR, the patient should be early sent for specialized cardiological examination, which includes echocardiography, myocardial scintigraphy, magnetic resonance imaging or myocardial biopsy. With early diagnosis, except for symptomatic treatment, there is also specific therapy available. In this case we present 76years-old polymorbid patient, repeatedly hospitalized for heart failure, who was diagnosed with transthyretin amyloidosis of the heart and we discusse current treatment options for this disease.
Keywords:
geriatric patient – case study – transthyretin heart amyloidosis – new treatment options
Sources
- Paleček T. Transthyretinová amyloidóza srdce: mysleme na ni! Svět praktické medicíny 2022; 3(2): 73–77.
- Paleček T, Krejčí J. Studie ATTR-ACT: přelom v léčbě transthyretinové srdeční amyloidózy. Interv Akut Kardiol 2019; 18(1): 45–48.
- Závodná R, Zeman K, Pleva M, et al. Difficulties in the diagnosis of cardiac amyloidosis and treatment options: case report. Vnitr Lek 2020; 66(1): 34–40.
- Alnylam. Presentation of 18-month results from the APOLLO-B phase study of patisiran in patients with ATTR amyloidosis with cardiomyopathy. Eastern Daylight Time, May 20, 2023.
- Aiglová R, Táborský M, Flodrová P, et al. Srdeční transthyretinová amyloidóza. Cor Vasa 2020; 62(3): 267–271.
- Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79: 785–792.
- APOLLO-B: Studie k vyhodnocení patisiranu u účastníků s trans-thyretinovou amyloidózou s kardiomyopatií (ATTR amyloidóza s kardiomyopatií). Alnylam Pharmaceuticals 15. března 2023.
- Urits I, Swanson D, Swett MC, et al. A review of patisiran (ONPATTRO) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther 2020; 9(2): 301–315.
- Ebhard AH. RNA interference (RNAi) patents and human health related applications of RNAi. Recent Pat DNA Gene Seq 2007; 1(2): 128–133.
Labels
Geriatrics General practitioner for adults Orthopaedic prostheticsArticle was published in
Geriatrics and Gerontology
2023 Issue 3
Most read in this issue
- Recommended tools for medication review and prescription optimization in geriatric patients
- Preoperative examination of the elderly in primary care. Joint recommended practice of the Society of General Medicine and the Czech Gerontological and Geriatric Society ČLS JEP
- Anticoagulant treatment in patients with atrial fibrillation and chronic kidney disease – a common problem in the elderly
- Transthyretin amyloidosis of the heart – a diagnosis to keep in mind even in old age